Rac-SFN has been shown to block multiple inflammasomes, such as the NLRP3 inflammasome [60], in in vivo animal models, including stroke [61], retinal vascular disorder [62], acute gout [63], peritonitis [64], non-alcoholic fatty liver disease [65], acute pancreatitis [66] and pulmonary arterial hypertension [67] models, and also in vitro studies using BMDMs differentiated from RAW 264.7 cells [68], a THP-1 human monocytic cell line [69] and microglia [70]. Here, SFN is linked to pulmonary arterial hypertension.